Welcome to our dedicated page for RxSight SEC filings (Ticker: RXST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RxSight, Inc. filings document the public-company record for a Nasdaq-listed ophthalmic medical device issuer centered on the RxSight Light Adjustable Lens system. Form 8-K reports furnish operating results, sales guidance, Light Adjustable Lens and Light Delivery Device commercial metrics, preliminary results and other material updates tied to financial condition.
The company’s proxy and governance filings cover annual meeting matters, board and committee composition, executive compensation, equity awards and stockholder voting procedures. Other current reports address officer appointments, transition agreements, compensatory arrangements and the registered common stock structure for RXST.
LINK WILLIAM J PHD reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director William J. Link received an equity grant of 37,037 shares of Common Stock as a stock award, with no cash paid per share. After this award, his directly held Common Stock position reported in this filing totals 74,892 shares.
The award is structured as restricted stock units, each representing a contingent right to one share of RxSight Common Stock. All RSUs vest 100% on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting, subject to his continuing as an Outside Director. Separately, 21,248 shares are held indirectly through Link Family Enterprise, L.P., where he may be deemed to share voting and investment power but disclaims beneficial ownership beyond his pecuniary interest.
Corley Jesse Anderson reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Corley Jesse Anderson received a grant of 37,037 restricted stock units (RSUs) of Common Stock as compensation. Each RSU represents one share and was granted at $0.00 per share. Subject to his continuing service as an Outside Director, all RSUs vest on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting. Following the grant, he holds 86,227 shares directly and additional indirect positions through the Andy Corley Living Trust, The Corley Foundation, the Juana McKay Living Trust, and shares held by his spouse.
COHEN RAYMOND W reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Raymond W. Cohen received a grant of 30,864 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest 100% on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting, subject to his continued service as an Outside Director. Following this equity award, Cohen holds 66,532 shares/RSUs of RxSight common stock directly.
Tammenoms Bakker Juliet reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. board member Juliet Tammenoms Bakker reported an equity compensation grant in the form of restricted stock units. She received 37,037 RSUs, each representing one share of RxSight common stock, at a price of $0.00 per share, increasing her direct holdings to 85,183 shares.
The RSUs vest 100% on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting, subject to her continued service as an Outside Director. She also has 1,548 shares held indirectly in a trust, where she may share voting and investment power but disclaims beneficial ownership beyond her economic interest.
Andrews Julie reported acquisition or exercise transactions in this Form 4 filing.
RxSight, Inc. director Julie Andrews received a grant of 37,037 restricted stock units, each representing a right to one share of common stock at no cost. The RSUs vest in full on the earlier of the one-year anniversary of the June 17, 2026 grant date or the next annual stockholder meeting, contingent on her continuing as an Outside Director. Following this award, she holds 78,076 shares directly.
RxSight, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 16, 2026. Of 41,396,609 common shares outstanding as of April 21, 2026, 33,299,192 were represented, about 80.4% of shares entitled to vote.
Stockholders re-elected three Class II directors — William J. Link, Robert Warner, and Shweta Singh Maniar — to serve until the 2029 annual meeting and until their successors are elected and qualified.
They also approved, on an advisory basis, executive compensation, with 21,236,615 votes for and 2,742,189 against, and ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 33,062,585 votes for and 92,653 against.
Artisan Partners filings report a disclosed beneficial ownership stake in RxSight, Inc. The filing states 2,058,684 shares beneficially owned, representing 5.0% of the class based on 41,266,335 shares outstanding as of 2/18/2026. The holders report 1,856,861 shares of shared voting power and 2,058,684 shares of shared dispositive power. The filing is a joint Schedule 13G/A amendment executed by multiple Artisan entities and signed on 05/13/2026.
RxSight, Inc. reported lower quarterly sales and a wider loss as growth in its premium cataract lens business slowed. For the three months ended March 31, 2026, sales were $30.9 million, down 18.5% from the prior year, mainly from fewer Light Delivery Device (LDD) sales, while Light Adjustable Lens (LAL) revenue was roughly flat.
Gross profit was $23.5 million with a gross margin of 76.1%, helped by a higher mix of LAL sales. Operating expenses rose to $41.3 million, driven by higher selling, general and administrative spending, and the net loss nearly doubled to $15.9 million. RxSight ended the quarter with $217.9 million in cash, cash equivalents and short-term investments and expects to continue operating losses while investing in commercial expansion and R&D.
RxSight, Inc. reported first quarter 2026 sales of $30.9 million, down 18.5% from a year earlier, mainly due to lower Light Delivery Device volumes, while Light Adjustable Lens procedures decreased 0.4% year over year. Gross profit margin improved to 76.1% from 74.8% on a richer lens mix.
Total operating expenses rose to $41.3 million from $39.0 million as the company expanded its global commercial and support teams. Net loss widened to $15.9 million, or $0.38 per share, versus $8.2 million, or $0.20 per share, with adjusted net loss at $7.9 million, or $0.19 per share. Cash, cash equivalents and short-term investments totaled $217.9 million as of March 31, 2026. RxSight reiterated 2026 revenue guidance of $120 to $135 million and gross margin guidance of 70% to 72%, and now expects operating expenses at the high end of its prior $150 to $160 million range.